HMN-214 IVX-214 HMN214 CAS: 173529-46-9 is a chemical compound that belongs to the class of chemotherapeutic drugs known as vinca alkaloids. It is an anti-cancer agent, a microtubule inhibitor that works by preventing the formation of the spindle fibers during cell division, thereby inhibiting the growth and proliferation of cancer cells. HMN-214 has been shown to have promising effectiveness in several preclinical studies, especially in the treatment of various forms of cancer. In this article, we will provide a comprehensive overview of HMN-214 IVX-214 HMN214 CAS: 173529-46-9, including its chemical structure, top ten keywords, synonyms, health benefits, potential side effects, dosing information, and safety.
The chemical name of HMN-214 IVX-214 HMN214 CAS: 173529-46-9 is desacetylvinblastine monohydrazide.
The molecular formula of HMN-214 IVX-214 HMN214 CAS: 173529-46-9 is C46H58N4O9.
The formula weight of HMN-214 IVX-214 HMN214 CAS: 173529-46-9 is 822.98 g/mol.
The CAS No of HMN-214 IVX-214 HMN214 CAS: 173529-46-9 is 173529-46-9.
Top Ten Keywords:
Desacetylvinblastine monohydrazide, Vinblastine derivative, HMN214, IVX-214.
The primary health benefit of HMN-214 IVX-214 HMN214 CAS: 173529-46-9 is that it functions as an anti-cancer agent. The drug has demonstrated promising results in several preclinical studies in vitro and in vivo, especially for the treatment of several types of cancer, including breast, colon, lung, ovarian, and prostate cancer. HMN-214 works by preventing the division of cancer cells during the mitotic process, thereby inhibiting the growth and proliferation of cancer cells. When combined with other anti-cancer agents, HMN-214 has shown significant synergistic effects, resulting in enhanced cancer cell death.
Potential Side Effects:
Like all chemotherapeutic drugs, HMN-214 IVX-214 HMN214 CAS: 173529-46-9 can also cause several potential side effects. The side effects of the drug may vary depending on the individual's health, the dosage, and the duration of the treatment. Some common side effects of HMN-214 include:
The dosing information of HMN-214 IVX-214 HMN214 CAS: 173529-46-9 may vary depending on several factors, such as the individual's health condition, the cancer type, and the severity of the disease. The drug is administered intravenously and typically given in a hospital or clinic setting. The recommended dose of HMN-214 varies from 0.3 mg/m2 to 2 mg/m2, administered on day 1 of a three-week cycle. The dosage and duration of the treatment may vary depending on the individual's response to the drug and other factors.
The primary mechanism of HMN-214 IVX-214 HMN214 CAS: 173529-46-9 is to inhibit the growth and proliferation of cancerous cells. HMN-214 functions as a microtubule inhibitor, preventing the formation of spindle fibers during cell division. This inhibition leads to the arrest of the cell cycle, halting the growth and division of the cancer cells. The drug also induces apoptosis, programmed cell death, in cancer cells, resulting in the destruction of these cells. Additionally, HMN-214 can overcome drug resistance and improve the effectiveness of other chemotherapeutic agents.
Like all drugs, HMN-214 IVX-214 HMN214 CAS: 173529-46-9 should be used under medical supervision. Pregnant and breastfeeding women should consult with their healthcare providers before using this drug. As the drug can cause several potential side effects like nausea, vomiting, and diarrhea, patients should be monitored closely for any adverse reactions. The drug should not be administered to a patient with severe liver or kidney problems.
HMN-214 IVX-214 HMN214 CAS: 173529-46-9 is a promising anti-cancer agent that functions as a microtubule inhibitor. The drug has shown excellent effectiveness in preclinical studies and has been used to treat various types of cancer. While the drug can cause several potential side effects, the benefits of using HMN-214 far outweigh the risks. HMN-214 may offer a new hope against cancer and combined with other chemotherapy agents may improve patient outcomes. Patients considering this drug should consult with their healthcare provider to better understand the potential benefits and risks before deciding on treatment.